Alnylam Pharmaceuticals (ALNY) stock surged 6.53% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results. The company's performance significantly exceeded analysts' expectations, demonstrating robust growth in key areas.

The biopharmaceutical firm reported total revenues of $773.7 million for Q2 2025, marking a 17% increase compared to the same period last year. Notably, total net product revenues reached $672 million, representing a substantial 64% year-over-year growth. This surge was primarily driven by the company's TTR franchise, which generated revenues of $544 million, up 77% from the previous year.

While Alnylam's GAAP net loss per share widened to $0.51 from $0.13 in Q2 2024, its non-GAAP earnings per share of $0.34 significantly outperformed the IBES estimate of -$0.77. The company's strong performance has led it to raise its 2025 guidance, projecting total net product revenues between $2.65 billion and $2.8 billion, representing a 27% increase at the midpoint. This optimistic outlook, coupled with recent regulatory approvals and the initiation of new clinical trials, has fueled investor confidence, contributing to the stock's pre-market rally.